First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

2025-521173-13-00 Protocol DS3610-071 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 3 sites · Protocol DS3610-071

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 70
Countries 2
Sites 3

Advanced Solid Tumors

Key facts

Sponsor
Daiichi Sankyo Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2026-05-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2025-521173-13-00
ClinicalTrials.gov
NCT07159126

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Daiichi Sankyo Inc.

Sponsor organisation
Daiichi Sankyo Inc.
Address
211 Mount Airy Road
City
Basking Ridge
Postcode
07920-2311
Country
United States

Scientific contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Public contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Clinical Trial Office

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 12 2
Spain Authorised, recruitment pending 12 1
Rest of world
United States, Japan
46

Investigational sites

France

2 sites · Authorised, recruitment pending
Oncopole Claudius Regaud
Oncologie médicale, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon

Spain

1 site · Authorised, recruitment pending
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-26 Spain Acceptable with conditions
2026-05-06
2026-05-08